An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes

Khanam, Saima; Pilankatta, Rajendra; Khanna, Navin; Swaminathan, Sathyamangalam

doi:10.1186/1472-6750-7-10

Cited by 34 publications

(6 citation statements)

References 47 publications

(73 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It appeared, therefore, that the 40-residue long ectodomain of M plays a critical role in its immunogenicity. DV EDIII has been previously shown to be immunogenic in the form of recombinant chimeric proteins [8] , [9] , [10] , [12] or expressed from a plasmid [51] or from adenovirus vector [52] , [53] . To determine whether the EDIII sequence inserted into MV vector was able to present neutralizing epitopes, we produced in E.coli recombinant EDIII proteins from DV1, 2, 3 and 4 corresponding to the same sequence and we coated plates with these proteins.…”

Section: Discussionmentioning

confidence: 99%

Pediatric Measles Vaccine Expressing a Dengue Antigen Induces Durable Serotype-specific Neutralizing Antibodies to Dengue Virus

et al. 2007

View full text Add to dashboard Cite

Dengue disease is an increasing global health problem that threatens one-third of the world's population. Despite decades of efforts, no licensed vaccine against dengue is available. With the aim to develop an affordable vaccine that could be used in young populations living in tropical areas, we evaluated a new strategy based on the expression of a minimal dengue antigen by a vector derived from pediatric live-attenuated Schwarz measles vaccine (MV). As a proof-of-concept, we inserted into the MV vector a sequence encoding a minimal combined dengue antigen composed of the envelope domain III (EDIII) fused to the ectodomain of the membrane protein (ectoM) from DV serotype-1. Immunization of mice susceptible to MV resulted in a long-term production of DV1 serotype-specific neutralizing antibodies. The presence of ectoM was critical to the immunogenicity of inserted EDIII. The adjuvant capacity of ectoM correlated with its ability to promote the maturation of dendritic cells and the secretion of proinflammatory and antiviral cytokines and chemokines involved in adaptive immunity. The protective efficacy of this vaccine should be studied in non-human primates. A combined measles–dengue vaccine might provide a one-shot approach to immunize children against both diseases where they co-exist.

show abstract

Section: Discussionmentioning

confidence: 99%

Pediatric Measles Vaccine Expressing a Dengue Antigen Induces Durable Serotype-specific Neutralizing Antibodies to Dengue Virus

et al. 2007

View full text Add to dashboard Cite

show abstract

“…For example, a recombinant adenovirus containing the two DIII regions from DENV-2 and DENV-4 was immunized in mice and later animals were boosted with a plasmid including the identical antigens. This prime-boost immunization strategy showed the induction of neutralizing antibodies and T-cell specific response to both DENV serotypes (67). Unfortunately, this study did not evaluate the protective capacity of this combination but taking into account the immunogenicity, this could be an interesting prospect.…”

Section: Complementary Prime-boost Immunization Strategies For the Dementioning

confidence: 99%

Can Complementary Prime-Boost Immunization Strategies Be an Alternative and Promising Vaccine Approach Against Dengue Virus?

et al. 2019

View full text Add to dashboard Cite

Dengue is one of the most important diseases transmitted by mosquitoes. Dengvaxia®, a vaccine registered in several countries, cannot be administered to non-immune individuals and children younger than 9 years old, due to safety reasons. There are two vaccine candidates in phase 3 efficacy trials, but their registration date is completely unknown at this moment. So, the development of new vaccines or vaccine strategies continues to be a priority for the WHO. This work reviews some complementary prime-boost immunization studies against important human pathogens. Additionally, it reviews the results obtained using this regimen of immunization against dengue virus as a potential alternative approach for finding a safe and efficient vaccine. Finally, the main elements associated with this strategy are also discussed. The generation of new strategies of vaccination against dengue virus, must be directed to reduce the risk of increasing viral load through sub-neutralizing antibodies and it must be also directed to induce a polyfunctional T cell response. Complementary prime-boost immunization strategies could emerge as an interesting approach to induce solid immunity or at least to reduce viral load after natural infection, avoiding severe dengue. Subunit vaccine could be safe and attractive antigens for this strategy, especially proteins including B, and T-cells epitopes for inducing humoral and cellular immune responses, which can play an important role controlling the disease.

show abstract

“…A heterologous prime-boost strategy involving a bivalent rAd vector (rAd-C) encoding a chimeric antigen comprised of the envelope domain III of DENV-2 and DENV-4 was evaluated in mice [ 46 ]. Mice were immunized with 10 8 PFU of rAd-C and then boosted 15 days later with a plasmid expressing the same chimeric antigen (pVAX-EDIII-4/2).…”

Section: Next Generation Vaccinesmentioning

confidence: 99%

Next-Generation Dengue Vaccines: Novel Strategies Currently Under Development

Durbin

Whitehead

2011

Viruses

View full text Add to dashboard Cite

Dengue has become the most important arboviral infection worldwide with more than 30 million cases of dengue fever estimated to occur each year. The need for a dengue vaccine is great and several live attenuated dengue candidate vaccines are proceeding through clinical evaluation. The need to induce a balanced immune response against all four DENV serotypes with a single vaccine has been a challenge for dengue vaccine developers. A live attenuated DENV chimeric vaccine produced by Sanofi Pasteur has recently entered Phase III evaluation in numerous dengue-endemic regions of the world. Viral interference between serotypes contained in live vaccines has required up to three doses of the vaccine be given over a 12-month period of time. For this reason, novel DENV candidate vaccines are being developed with the goal of achieving a protective immune response with an immunization schedule that can be given over the course of a few months. These next-generation candidates include DNA vaccines, recombinant adenovirus vectored vaccines, alphavirus replicons, and sub-unit protein vaccines. Several of these novel candidates will be discussed.

show abstract

An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes

Cited by 34 publications

References 47 publications

Pediatric Measles Vaccine Expressing a Dengue Antigen Induces Durable Serotype-specific Neutralizing Antibodies to Dengue Virus

Pediatric Measles Vaccine Expressing a Dengue Antigen Induces Durable Serotype-specific Neutralizing Antibodies to Dengue Virus

Can Complementary Prime-Boost Immunization Strategies Be an Alternative and Promising Vaccine Approach Against Dengue Virus?

Next-Generation Dengue Vaccines: Novel Strategies Currently Under Development

Contact Info

Product

Resources

About